Houston biomedical startup granted $1.5M, Chevron taps into Plug and Play, and more innovation news

Short stories

Money moves, big deals, and more lead this roundup of innovation news. Pexels

Hitting headlines this month are innovation news stories from battling the opioid crisis and funding to TMCx companies and Houston as a whole earning recognition.

In this innovation news roundup, two Houston startups pocket some cash, Chevron links up with Plug and Play, and more.

BreviTest receives grant to combat opioid crisis

Houston-based BreviTest can rapidly and accurately test for opioid use. Photo via brevitest.com

National Institute on Drug Abuseof the National Institutes of Health — through a Small Business Innovation Research Phase II grant — has granted $1.5 million to Houston-based BreviTest Technologies to take its opioid testing technology to the next level. With 47,600 opioid overdose deaths reported in 2017 in the United States, the startup's analyzer has a lot of potential to aid in the crisis.

"Because of the delay in receiving laboratory results, many physicians use urine drug testing sparingly. The BreviTest analyzer will allow any doctor to measure opioid urine levels in-office, which will help them identify individuals who are misusing the drugs," says BreviTest's Michael J. Heffernan, Ph.D., principal investigator on the project, in a news release.

BreviTest is a Fannin Innovation Studio company. The early-stage biomedical commercialization firm that's based in Houston is proud to see the startup's success and the difference the technology is making.

"Our BreviTest team is excited to receive this support from NIDA to advance our point-of-care diagnostics technology into the clinic," said Fannin executive chairman, Leo Linbeck III, in the release. "Putting a convenient, accurate opioid test in the hands of physicians will be an important step in combating the opioid overdose epidemic facing our country."

Houston's Plug and Play operation names Chevron as founding partner

Chevron has linked up with Plug and Play in Houston. Courtesy of CTV

Plug and Play Tech Center, which just announced the participating companies in its inaugural energy and sustainability cohort in Houston, has named Chevron as a founding partner.

"We are incredibly excited to announce Chevron as a Founding Partner of Plug and Play in Houston," saysWade Bitaraf, founder of Plug and Play's Energy & Sustainability program, in a news release. "Their commitment to invest in digital transformation and reduce the environmental impact of the industry is directly aligned with our Energy & Sustainability program in Houston, Silicon Valley, and around the world."

Barbara Burger, president of Chevron Technology Ventures, the company's venture and innovation arm, is responsible for identifying pathways to innovation for the company.

"Chevron is a proud supporter of the Houston innovation community, and our support of Plug and Play's Energy & Sustainability platform demonstrates our commitment to growing the Houston innovation ecosystem," Burger says in the release. "Innovation will play a critical role in the future of energy, and our partnership with Plug and Play reinforces our commitment to invest in breakthrough technologies to enable the ongoing energy transition."

Houston recognized as a top 10 city for female founder success

According to Inc. 5000, Houston's great for female founders. Getty Images

Texas cities are great for fostering female founder success, according to a new ranking from Inc. 5000. Houston ranked at No. 10 of the top 10 list that factored in the women-led businesses among the magazine's 5,000 fastest-growing private U.S. companies.

"The Houston metropolitan area is home to 15 women-owned Inc. 5000 companies, including online marketing startup Decode Digital Marketing (No. 973) and health care staffing firm Restore Rehab Services (No. 2,645)," reads the ranking. "Together the 15 firms grew their collective revenue 142 percent between 2015 and 2018."

Dallas and Austin both appeared on the ranking, at No. 4 and No. 6, respectively.

Alice closes series A of funding

Alice founders, Elizabeth Gore (left) and Carolyn Rodz, closed their series A of funding. Getty Images

Though the company did not disclose an amount raised, Alice, an artificial intelligence-powered platform for business advice, closed a series A funding round led by SVB Financial Group, the parent company to Silicon Valley Bank.

Per a news release, the company will use the funding to "build its predictive technology, using data analytics to guide each entrepreneur through every stage of their business."

Alice, which has operations in Houston and San Francisco, reached a deal with Austin-based Bumble for funding earlier this year.

TMCx companies win big

Three TMCx alumni companies earned some recognition at the UCSF Digital Health Awards last month. Courtesy of TMCx

Three health tech companies coming out of the Texas Medical Center's accelerator program have won big at the UCSF Digital Health Awards last month.

Sana Health, member of TMCx07 in 2018, won in the best behavioral health digital therapeutic category for its light-based neuromodulation pain treatment technology.
Meru Health, member of TMCx08 in 2019, won in the best mental health digital health therapeutic category for its mental health platform.
Luma Health, member of TMCx08 in 2019, won in the best EHR-integrated platform for patient engagement category for its patient communication technology.

Ad Placement 300x100

Ad Placement 300x600

CultureMap Emails are Awesome

Property Showcase

Play it back: Houston home tech startup begins 2025 with fresh funding

HOUSTON INNOVATORS PODCAST EPISODE 272

One of the dozen or so Houston startups kicking of the new year with fresh funding is SmartAC.com, a company that's designed a platform that enables contractors in the HVAC and plumbing industries to monitor, manage, and optimize their maintenance memberships through advanced sensors, AI-driven diagnostics, and proactive alerts.

Last month, the SmartAC.com raised a follow-on round with support from local investor Mercury to continue growth and expansion of the product, which has evolved on many ways since the company launched in 2020, emerging from stealth with $10 million raised in a series A. In a May 2023 interview for the Houston Innovators Podcast, Founder and CEO Josh Teekell explained how he embraced the power of a pivot.

The company's sensors can monitor all aspects of air conditioning units and report back any issues, meaning homeowners have quicker and less costly repairs. While SmartAC.com started with providing the service and tech to homeowners directly, Teekell says he's had a greater interest in working with plumbers and HVAC companies who then deploy the technology to their customers.

"It became quite evident that homeowners don't care about air conditioning really at all until their system breaks," Teekell says on the show. "The technology is really built around giving those contractors as another way to gain a customer relationship and keep it."

Revisit the podcast episode below where Teekell talks about SmartAC.com's last raise.

SmartAC.com's previous round in 2023 — a $22 million series B — was used grow its team that goes out to deploy the technology and train the contractors on the platform.

"We've been very fortunate to get some of the biggest names in Houston on our cap table," Teekell says in the May 2023 conversation. "Since we're raising a bunch of money locally, everyone understands what a pain air conditioning can be."

Houston biotech company tests hard-to-fight cancer therapeutics

fighting cancer

A Houston-based, female-founded biotech company has developed a treatment that could prove to be an effective therapy for a rare blood cancer.

Cellenkos Therapeutics has completed promising Phase 1b testing of its Treg cell therapy, CK0804, in the fight against myelofibrosis. According to a news release from the Cellenkos team, the use of its cord-blood-derived therapeutics could signal a paradigm shift for the treatment of this hard-to-fight cancer.

Cellenkos was founded by MD Anderson Cancer Center physician and professor Simrit Parmar. Her research at the hospital displayed the ability of a unique subset of T cells’ capability to home in on a patient’s bone marrow, restoring immune balance, and potentially halting disease progression.

Myelofibrosis has long been treated primarily with JAK (Janus Kinase) inhibitors, medications that help to block inflammatory enzymes. They work by suppressing the immune response to the blood cancer, but don’t slow the progression of the malady. And they’re not effective for every patient.

“There is a significant need for new therapeutic options for patients living with myelofibrosis who have suboptimal responses to approved JAK inhibitors,” Parmar says. “We are greatly encouraged by the safety profile and early signs of efficacy observed in this patient cohort and look forward to continuing our evaluation of the clinical potential of CK0804 in our planned expansion cohort.”

The expansion cohort is currently enrolling patients with myelofibrosis. What exactly are sufferers dealing with? Myelofibrosis is a chronic disease that causes bone marrow to form scar tissue. This makes it difficult for the body to produce normal blood cells, leaving patients with fatigue, spleen enlargement and night sweats.

Myelofibrosis is rare, with just 16,000 to 18,500 people affected in the United States. But for patients who don’t respond well to JAKs, the prognosis could mean a shorter span than the six-year median survival rate outlined for the disease by Cleveland Clinic.

Helping myelofibrosis patients to thrive isn’t the only goal for Cellenkos right now.

The company seeks to aid people with rare conditions, particularly inflammatory and autoimmune disorders, with the use of CK0804, but also other candidates including one known as CK0801. The latter drug has shown promising efficacy in aplastic anemia, including transfusion independence in treated patients.

The company closed its $15 million series A round led by BVCF Management, based in Shanghai, in 2021. Read more here.

Pioneering Houston biotech startup expands to Brazil for next phase

On the Move

Houston biotech company Cemvita has expanded into Brazil. The company officially established a new subsidiary in the country under the same name.

According to an announcement made earlier this month, the expansion aims to capitalize on Brazil’s progressive regulatory framework, including Brazil’s Fuel of the Future Law, which was enacted in 2024. The company said the expansion also aims to coincide with the 2025 COP30, the UN’s climate change conference, which will be hosted in Brazil in November.

Cemvita utilizes synthetic biology to transform carbon emissions into valuable bio-based chemicals.

“For decades Brazil has pioneered the bioeconomy, and now the time has come to create the future of the circular bioeconomy,” Moji Karimi, CEO of Cemvita, said in a news release. “Our vision is to combine the innovation Cemvita is known for with Brazil’s expertise and resources to create an ecosystem where waste becomes opportunity and sustainability drives growth. By joining forces with Brazilian partners, Cemvita aims to build on Brazil’s storied history in the bioeconomy while laying the groundwork for a circular and sustainable future.”

The Fuel of the Future Law mandates an increase in the biodiesel content of diesel fuel, starting from 15 percent in March and increasing to 20 percent by 2030. It also requires the adoption of Sustainable Aviation Fuel (SAF) and for domestic flights to reduce greenhouse gas emissions by 1 percent starting in 2027, growing to 10 percent reduction by 2037.

Cemvita agreed to a 20-year contract that specified it would supply up to 50 million gallons of SAF annually to United Airlines in 2023.

"This is all made possible by our innovative technology, which transforms carbon waste into value,” Marcio Da Silva, VP of Innovation, said in a news release. “Unlike traditional methods, it requires neither a large land footprint nor clean freshwater, ensuring minimal environmental impact. At the same time, it produces high-value green chemicals—such as sustainable oils and biofuels—without competing with the critical resources needed for food production."

In 2024, Cemvita became capable of generating 500 barrels per day of sustainable oil from carbon waste at its first commercial plant. As a result, Cemvita quadrupled output at its Houston plant. The company had originally planned to reach this milestone in 2029.

---

This story originally appeared on our sister site, EnergyCapitalHTX.

View All Listings

INNOVATIONMAP EMAILS ARE AWESOME